CERo Therapeutics Holdings, Inc. (CERO) Fair Value 2026

CERO · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

3.5 /10

32 fundamental signals · 1 models active

Value Trap Risk

WARN (41/100)

Quick Summary — As of 2026-08-27, CERo Therapeutics Holdings, Inc. (CERO) trades at $0.01. QOC: 3.5/10. Value Trap Risk: 41/100 (WARN). 1/13 models active.

Key Facts

Ticker
CERO
Price
$0.01
Quality Score
3.5/10
Value Trap Risk
41/100
Models Active
1/13
Last Updated
Strength: PWERM suggests +71.9% upside with 29% confidence
Risk: Value Trap score of 41 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give CERO?

1 Intrinsic Value Models vs. Current Price ($0.01)

Core Models (Unlocked)
Model Fair Value Upside
Option-Based · Medium Conviction
 $0.02 +71.9%

All Models Active

All 1 models are displayed above.

What Is CERo Therapeutics Holdings, Inc. (CERO) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the weight of evidence tilts decidedly bullish for CERo Therapeutics Holdings, Inc.. Trading at $0.01 against an estimated intrinsic value of $0.02, 1 of 1 active models flag meaningful upside of +71.9% at the median.

What Do the Models Say About CERO?

1 of 13 models are currently active for CERO. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does CERO Rank in Biotechnology?

Among 620 Biotechnology stocks, CERO ranks #567 by Quality of Company score. CirclFi's QOC score of 3.5/10 evaluates 32 fundamental signals. A score of 3.5 signals below-average fundamentals.

See all Most Undervalued Biotechnology Stocks →

As a biotech sector, CERo Therapeutics Holdings, Inc. operates in a sector where partnership revenue is a critical driver of valuation. Investors evaluating CERO should weigh these sector-specific dynamics alongside our model-derived fair values.

Is CERO a Value Trap?

CirclFi's Value Trap algorithm assigns CERO a score of 41/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for CERo Therapeutics Holdings, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, CERo Therapeutics Holdings, Inc.'s fundamental quality profile registers 3.5/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every CERO valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across CERO's 1 active models, average confidence is 29%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy CERo Therapeutics Holdings, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

LNAILunai Bioworks Inc.QOC 3.5COAGHemab Therapeutics Holdings, Inc.QOC 3.5AKTSAktis Oncology, Inc.QOC 3.5GENBGenerate Biomedicines, Inc.QOC 3.5CNBXCNBX Pharmaceuticals Inc.QOC 3.6PCSAProcessa Pharmaceuticals, Inc.QOC 3.5XNCRXencor, Inc.QOC 6.4GOSSGossamer Bio, Inc.QOC 5.2OGENOragenics, Inc.QOC 4.6EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: LNAI · COAG · AKTS · GENB · CNBX · PCSA · XNCR · GOSS · OGEN · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to CERO?

6 companies across all industries closest to CERO’s Quality of Company score of 3.5/10.

GTCHGBT Technologies Inc.QOC 3.5KITTNauticus Robotics, Inc.QOC 3.5MGTIMGT Capital Investments, Inc.QOC 3.5HQHorizon Quantum Holdings Ltd.QOC 3.5ATMHAll Things Mobile Analytic Inc.QOC 3.5NVDANVIDIA CorporationQOC 10.0

Read investment analysis: GTCH · KITT · MGTI · HQ · ATMH · NVDA

Where Does CERO Sit in CirclFi's Biotechnology Rankings?

CERO is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About CERo Therapeutics Holdings, Inc.’s Valuation?

What is CERo Therapeutics Holdings, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for CERo Therapeutics Holdings, Inc. (CERO). The Quality of Company score is 3.5/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is CERO overvalued or undervalued right now?

At $0.01, 1 of 1 active models suggest CERO may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits CERo Therapeutics Holdings, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 3.5 mean for CERO?

CERo Therapeutics Holdings, Inc.'s QOC of 3.5/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on CERO?

CirclFi analyzes CERO with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is CERO a value trap in 2026?

CERo Therapeutics Holdings, Inc.'s Value Trap score is 41/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns CERo Therapeutics Holdings, Inc. (CERO) a Quality of Company score of 3.5/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/CERO/ · Methodology
Primary sources for this CERO valuation
  • Financial statements: CERo Therapeutics Holdings, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001870404) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for CERO as of ; valuations recomputed .